CENTRAL DATA COLLECTION CENTER (CDCC) CONTINUED FOLLOW-UP OF PLCO

中央数据收集中心（CDCC）持续跟进PLCO

• 批准号: 8441458
• 负责人: BARBARA O'BRIEN
• 金额: $ 268.52万
• 依托单位: WESTAT, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-03-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8441458
• 关键词: Biological; Clinical Data; Collection; Colon; Colorectal; Colorectal Cancer; Data; Data Collection; Data Coordinating Center; Diagnostic; Elderly; Epidemiologic Studies; Epidemiology; Life Style; Long-Term Effects; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Medical; Molecular; National Cancer Institute; Ovarian; Ovary; Participant; Pharmaceutical Preparations; Prostate; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; Questionnaires; Resources; Risk; Sampling; Screening for Prostate Cancer; Screening procedure; Site; Tumor Tissue; Update; cost; design; follow-up; mortality; tumor; tumor registry

The PLCO Central Data Coordinating Center (CDCC) is an extension of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. To reduce costs, the extension has one data collection site under the direction of the National Cancer Institute (NCI) rather than the original ten PLCO Screening Centers. PLCO participants were invited to be transferred to the CDCC for continued, active follow up. Other participants agreed to be passively followed at the PLCO sites through tumor registry searches. PLCO was designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers. In addition, PLCO has a collection of pre- and post-diagnostic biological samples stored in the PLCO Biorepostory, and epidemiological data from questionnaires. These data are a valuable resource for cutting-edge molecular epidemiologic research. The study was extended in this streamlined fashion to increase the value of the resource. The study will continue to update key exposure data by collecting additional risk and lifestyle information, including medication use and medical conditions that are common in older adults. Also, the CDCC will collect additional clinical data and tumor tissue of selected cancers, such as that of the colon and ovaries. This extension of the PLCO Cancer Screening Trial enhances the value of the PLCO resources through the substantial increase in the number of incident cancers accrued within the Trial, strengthens the Trial's ability to clarify further the long-term effects of screening on cancer mortality, and provides a final opportunity to collect additional exposure data and expand the existing tumor pathological resource within the PLCO.

PLCO中央数据协调中心（CDCC）是前列腺、肺、结直肠和卵巢（PLCO）癌症筛查试验的扩展。为了降低成本，该扩展项目在国家癌症研究所（NCI）的指导下建立了一个数据收集站点，而不是原来的10个PLCO筛查中心。PLCO的参与者被邀请转到发合会，以便继续采取积极的后续行动。其他参与者同意通过肿瘤登记研究在PLCO网站被动随访。PLCO旨在确定前列腺癌，肺癌，结肠直肠癌和卵巢癌的筛查是否可以降低这些癌症的死亡率。此外，PLCO还收集了诊断前和诊断后的生物样本，储存在PLCO生物储存库中，并收集了问卷调查中的流行病学数据。这些数据是尖端分子流行病学研究的宝贵资源。以这种简化的方式延长了研究，以增加资源的价值。该研究将通过收集额外的风险和生活方式信息，包括老年人常见的药物使用和医疗条件，继续更新关键暴露数据。此外，CDCC将收集选定癌症的其他临床数据和肿瘤组织，如结肠和卵巢癌。PLCO癌症筛查试验的这一扩展通过大幅增加试验中累积的偶发癌症数量来提高PLCO资源的价值，加强试验进一步阐明筛查对癌症死亡率的长期影响的能力，并提供收集额外暴露数据和扩大PLCO内现有肿瘤病理学资源的最终机会。